Eloxx Pharmaceuticals (United States)

Eloxx Pharmaceuticals is a company in Waltham, United States. It is advancing exaluren for genetically defined patient subsets with Alport syndrome and ADPKD caused by nonsense mutations. Exaluren is a novel eukaryotic ribosome-selective glycoside product candidate designed to induce premature termination codon readthrough in the presence of nonsense mutations and promote the restoration of full-length proteins.

Eloxx Pharmaceuticals is a company in Waltham, United States. It is advancing exaluren for genetically defined patient subsets with Alport syndrome and ADPKD caused by nonsense mutations. Exaluren is a novel eukaryotic ribosome-selective glycoside product candidate designed to induce premature termination codon readthrough in the presence of nonsense mutations and promote the restoration of full-length proteins.

• exaluren

  A novel eukaryotic ribosome-selective glycoside product candidate designed to induce premature termination codon readthrough in the presence of nonsense mutations and promote the restoration of full-length proteins.

• 2026.10.19

  Reported2026.10.19

  Eloxx appoints Geno Germano to its board[4]Eloxx任命Geno Germano为董事会成员prnewswire.com

  Eloxx Pharmaceuticals announced the appointment of Geno Germano to its Board of Directors, effective October 19, 2026.

Read more

1. 1Home - Eloxx Pharmaceuticalseloxxpharma.com
2. 2About - Eloxx Pharmaceuticalseloxxpharma.com
3. 3Eloxx Pharmaceuticals (United States)wikidata.org
4. 4Eloxx任命Geno Germano为董事会成员prnewswire.com